Eli Lilly and Co (XSWX:LLY) Selling, General, & Admin. Expense: CHF9,226 Mil (TTM As of Mar. 2026)


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF970.00
GF Value CHF1,127.75
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Selling, General, & Admin. Expense?

Eli Lilly and Co XSWX:LLY 100 Selling, General, & Admin. Expense is CHF9,226 Mil as of Mar. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,127.75 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Eli Lilly and Co's selling, general, & admin. expense for the three months ended in Mar. 2026 was CHF2,310 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF9,226 Mil.


Eli Lilly and Co  (XSWX:LLY) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Eli Lilly and Co Selling, General, & Admin. Expense Related Terms


Eli Lilly and Co Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Selling, General, & Admin. Expense Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,923.50 5,999.88 6,402.98 7,662.41 8,840.81

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,180.73 2,238.74 2,181.87 2,495.41 2,309.94

XSWX:LLY vs JNJ, ABBV, MRK: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Selling, General, & Admin. Expense falls into.


XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF9,226 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of CHF9,226 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Selling, General, & Admin. Expense of CHF9,226 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Selling, General, & Admin. Expense too high?
Eli Lilly and Co's current Selling, General, & Admin. Expense is CHF9,226 Mil. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Selling, General, & Admin. Expense compare to JNJ and ABBV?
Eli Lilly and Co's Selling, General, & Admin. Expense of CHF9,226 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Selling, General, & Admin. Expense is CHF9,226 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,127.75, compared to a current price of CHF970.00 — trading 14% below its estimated fair value. The current Selling, General, & Admin. Expense is CHF9,226 Mil. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Selling, General, & Admin. Expense is CHF9,226 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF970.00 is trading 14% below its estimated GF Value™ of CHF1,127.75. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Selling, General, & Admin. Expense: CHF9,226 Mil
  • GF Value™: CHF1,127.75 vs. price of CHF970.00 (14% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF970.00
Price
CHF1,127.75
GF Value